Platelet polymorphism rs5918T > C in the integrin B3 gene modulates comorbidities in patients with psoriasis

Figures & data

Table 1. Anthropometric and clinical data, mean age, Body mass index (BMI), psoriasis area severity index (PASI), cardiovascular disease (CVD), hypertension, diabetes type II, psoriatic arthritis and metabolic syndrome of the patients included in the study and the mean age and BMI of controls.

Parameters	Patients mean ± SD	Controls means ± SD
Number of subjects	102	97
Mean age (years)	53.87 ± 12.60	52.40 ± 14.82
Age at diagnosis (years)	36.24 ± 15.52
BMI (kg/m^2)	29.17 ± 5.63	24.35 ± 3.90
PASI score	26.29 ± 9.21
Hypertension	61 (59.8%)
Diabetes Type II	20 (19.61%)
CVD	33 (32.35%)
Metabolic syndrome	39 (38.4%)
Psoriatic arthritis	35 (34.3%)

Table 2. Prevalence of ITGB3 rs5918(C) genotype, allele frequency, odds ratio (OR), Chi-squared, 95% confidence interval and Fisher’s exact test in psoriatic patients versus controls.

Genotypes and Allele frequencies of ITGB3 rs5918T > C	Prevalence in patients (%)	Prevalence in controls (%)	Chi-squared (χ2)	OR	95% Confidence interval	Fisher’s exact test
Heterozygous + homozygous (CT + CC)	21 (20.6)	18 (18.6)	0.2452	1.24621	0.5709 − 2.3250	p = . 518
Homozygous (TT)	81 (79.4)	79 (81.4)
T	90 (88.5)	91 (90.72)				p = .506
C	12 (11.5)	9 (9.28)				p = .314

Table 3. Incidence rates for psoriatic patients carriers of the ITGB3 rs5918(C) allele versus non-carriers of the polymorphism for high BMI, hyperglycemia, triglyceridemia, low HDL, hypercholesterolemia, dyslipidemia, hypertension, high CRP, PASI score >20, cardiovascular disease, metabolic syndrome and total comorbidities.

Parameters	Carriers of ITGB3 rs5918(C) Mean ± SD (%)	Non-carriers of ITGB3 rs5918(C) Mean ± SD (%)	Chi-squared	Odds ratio (OR)	p Value
Number of subjects	21	44
Mean age (years)	55.65 ± 9.96	54.27 ± 18.41			0.741
Patients with BMI ≥ 30 kg/m^2	11 (52.4)	19 (44.2)	0.9	1.4	.478
Patients with BMI ≥ 25 kg/m^2	19 (95)	35 (81.4)	2.1	4.3	.110
Patients with hyperglycemia	7 (33.3)	11 (25.0)	1.1	1.50	.322
Patients with triglyceridemia	9 (42.9)	11 (27.5)	1.98	1.5	.034
Patients with low HDL	10 (47.6)	13 (32.8)	3.8	3.4	.0385
Patients with hypercholesterolemia	15 (66.7)	20 (45.5)	2.29	2.167	.050
Patients with dyslipidemia	18 (85.7)	28 (63.6)	3.4	2.7	.019
Patients with Hypertension	14 (66.7)	26 (59.1)	0.701	1.4	.322
Patients with Diabetes Type II	5 (23.8%)	4 (9.1%)	2.582	3.125	. 214
Patients with high CRP	10 (47.6.)	14 (33.3)		1.8.0	.511
CRP (mg/L)	7.18 ± 7.27	5.05 ± 16.71			.330
Patients with PASI scores > 20	19 (92.5)	32 (73.3)	1.97	4.3	.210
PASI score	28.03 ± 12.36	25.90 ± 8.33			.0421
Cardiovascular disease	7 (33.3)	12 (27.3)		1.20	.721
Metabolic syndrome	11 (52.4)	9 (20.5)	6.8	4.3	.058
Psoriatic arthritis	6 (28.7)	12 (27.3)		1.00	.531
Total comorbidities related to CVD	33/21 (1.6)	45/44 (1.02)	4.8		.050

Data availability statement

The data that support the findings of this study are available from the corresponding author [R.K.-P.] upon reasonable request.